MA35865B1 - Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant - Google Patents

Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Info

Publication number
MA35865B1
MA35865B1 MA37207A MA37207A MA35865B1 MA 35865 B1 MA35865 B1 MA 35865B1 MA 37207 A MA37207 A MA 37207A MA 37207 A MA37207 A MA 37207A MA 35865 B1 MA35865 B1 MA 35865B1
Authority
MA
Morocco
Prior art keywords
vhc
pharmaceutical formulations
inhibitor
potent
control
Prior art date
Application number
MA37207A
Other languages
English (en)
Inventor
Mathias Braun
Carl Alan Busacca
Feng-Jing Chen
Edwin Louis Gump
Jenness B Majeska
Scott Pennino
Fenghe Qiu
Maria Fernanda Villagra
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47628447&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35865(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA35865B1 publication Critical patent/MA35865B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne divers procédés de stabilisation de formulations pharmaceutiques d'un inhibiteur spécifique du virus de l'hépatite c (vhc) dirigé contre la formation d'un produit de dégradation génotoxique particulier. De tels procédés incluent la régulation de la température, la régulation de l'humidité, la régulation de l'excipient, la régulation de la coquille de la capsule, la basification et une approche de reconstitution.
MA37207A 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant MA35865B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261586087P 2012-01-12 2012-01-12
PCT/US2013/020934 WO2013106506A1 (fr) 2012-01-12 2013-01-10 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Publications (1)

Publication Number Publication Date
MA35865B1 true MA35865B1 (fr) 2014-12-01

Family

ID=47628447

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37207A MA35865B1 (fr) 2012-01-12 2014-07-11 Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant

Country Status (27)

Country Link
US (2) US20140037719A1 (fr)
EP (1) EP2802313A1 (fr)
JP (1) JP2015503616A (fr)
KR (1) KR20140109433A (fr)
CN (1) CN104244926A (fr)
AP (1) AP2014007760A0 (fr)
AR (1) AR089710A1 (fr)
AU (1) AU2013208024A1 (fr)
BR (1) BR112014017058A8 (fr)
CA (1) CA2861041A1 (fr)
CL (1) CL2014001783A1 (fr)
CO (1) CO7000774A2 (fr)
EA (1) EA201400808A1 (fr)
EC (1) ECSP14013104A (fr)
HK (1) HK1204982A1 (fr)
IL (1) IL233550A0 (fr)
IN (1) IN2014DN05759A (fr)
MA (1) MA35865B1 (fr)
MX (1) MX2014008205A (fr)
NZ (1) NZ626353A (fr)
PE (1) PE20141817A1 (fr)
PH (1) PH12014501598A1 (fr)
SG (1) SG11201404042VA (fr)
TN (1) TN2014000295A1 (fr)
TW (1) TW201340969A (fr)
UY (1) UY34569A (fr)
WO (1) WO2013106506A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
JP6511432B2 (ja) 2013-03-15 2019-05-15 ギリアード サイエンシーズ， インコーポレイテッド Ｃ型肝炎ウイルスの大環状二環式阻害剤

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5329976A (en) * 1991-12-09 1994-07-19 Habley Medical Technology Corporation Syringe-filling and medication mixing dispenser
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UY28240A1 (es) * 2003-03-27 2004-11-08 Boehringer Ingelheim Pharma Fases cristalinas de un potente inhibidor de la hcv
CL2004001161A1 (es) 2003-05-21 2005-04-08 Boehringer Ingelheim Int Compuestos describe compuestos derivados de quinolina; composicion farmaceutica; y su uso para tratar una enfermedad causada por el virus de la hepatitis c.
EP1753775B1 (fr) 2004-05-25 2012-12-26 Boehringer Ingelheim International GmbH Processus de preparation d'inhibiteurs de protease hcv acyclique
WO2006130552A2 (fr) * 2005-06-02 2006-12-07 Schering Corporation Methodes de traitement du virus de l'hepatite c
AU2009293494B2 (en) 2008-09-16 2014-04-24 Boehringer Ingelheim International Gmbh Crystalline forms of a 2-thiazolyl- 4-quinolinyl-oxy derivative, a potent HCV inhibitor
EP2358355B1 (fr) 2008-11-21 2013-11-06 Boehringer Ingelheim International GmbH Composition pharmaceutique d'un inhibiteur puissant du vhc pour une administration orale
PE20120322A1 (es) 2009-07-07 2012-04-14 Boehringer Ingelheim Int Composicion farmaceutica que comprende faldaprevir o una sal del mismo en un vehiculo auto-emulsionante

Also Published As

Publication number Publication date
NZ626353A (en) 2016-02-26
PH12014501598A1 (en) 2014-10-08
US20140037719A1 (en) 2014-02-06
MX2014008205A (es) 2014-08-08
JP2015503616A (ja) 2015-02-02
SG11201404042VA (en) 2014-08-28
AU2013208024A1 (en) 2014-07-10
HK1204982A1 (en) 2015-12-11
IL233550A0 (en) 2014-08-31
BR112014017058A8 (pt) 2017-07-04
AR089710A1 (es) 2014-09-10
ECSP14013104A (es) 2015-11-30
PE20141817A1 (es) 2014-12-17
IN2014DN05759A (fr) 2015-04-10
US20150190458A1 (en) 2015-07-09
BR112014017058A2 (pt) 2017-06-13
CN104244926A (zh) 2014-12-24
AP2014007760A0 (en) 2014-07-31
EA201400808A1 (ru) 2015-02-27
CA2861041A1 (fr) 2013-07-18
WO2013106506A1 (fr) 2013-07-18
TW201340969A (zh) 2013-10-16
CL2014001783A1 (es) 2014-12-12
KR20140109433A (ko) 2014-09-15
EP2802313A1 (fr) 2014-11-19
CO7000774A2 (es) 2014-07-21
UY34569A (es) 2013-07-31
TN2014000295A1 (en) 2015-12-21

Similar Documents

Publication Publication Date Title
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
IL233830A0 (en) Preparations of 3-(6-(1-(2,2-difluorobenzo{0}{1,3}dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, methods for their staining and uses thereof
MX2014003886A (es) Composiciones farmaceuticas de n-metil-2-[3-((e) 2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]benzamida.
MY178082A (en) Solid pharmaceutical compositions and processes for their production
TN2015000281A1 (fr) Lactames condenses aryliques et heteroaryliques
WO2014016754A3 (fr) Compositions pharmaceutiques d'inhibiteur de la pompe à protons
WO2013003827A3 (fr) Formulations de macrogol 15 hydroxystéarate
IN2013CH05441A (fr)
MD20150053A2 (ro) Produs de comicronizare cu conţinut de acetat de ulipristal
WO2013175494A3 (fr) Formulations pharmaceutiques à libération contrôlée d'inhibiteurs directs de la thrombine
TN2012000507A1 (en) Enteric tablet
WO2014033526A9 (fr) Compositions pharmaceutiques d'étoricoxib
WO2010144339A3 (fr) Antagoniste du récepteur de la thrombine et comprimé de clopidogrel à dose fixe
MX2013007661A (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos.
PL2247573T3 (pl) Sole kwasu węglowego i siarkowego estrów 3-(2,2,2-trimetylohydrazynio)propionianów, oraz ich zastosowanie do wytwarzania dihydratu 3-(2,2,2-trimetylohydrazynio)propionianu
NZ701103A (en) Solid state forms of n-((s)-2,3-dihydroxy-propyl)-3-(2-fluoro-4-iodo-phenylamino)-isonicotinamide
PH12014501598A1 (en) Stabilized pharmaceutical formulations of a potent hcv inhibitor
WO2016069542A3 (fr) Composés de lactone, leurs procédés de préparation et d'utilisation
PL3882244T3 (pl) ZWIĄZEK, JEGO FARMACEUTYCZNIE DOPUSZCZALNA SÓL LUB IZOMER OPTYCZNY, SPOSÓB ICH WYTWARZANIA i ZAWIERAJĄCA JE, JAKO SKŁADNIK AKTYWNY, KOMPOZYCJA FARMACEUTYCZNA DO PROFILAKTYKI LUB LECZENIA CHORÓB WIRUSOWYCH
WO2013124832A3 (fr) Composition pharmaceutique à libération contrôlée stabilisée comprenant du gliclazide
MX2017008931A (es) Formulaciones farmaceuticas de xantina o derivados de xantina.
PH12013502080A1 (en) Modified release pharmaceutical compositions of desvenlafaxine
WO2011115599A3 (fr) Formulations de comprimé délitant par voie orale de donépézil et procédé pour préparer celui-ci
WO2013168179A3 (fr) Formulations pharmaceutiques à libération contrôlée d'agents antiviraux
UA110882C2 (uk) Фармацевтична композиція та спосіб її отримання